黄楚顺,赵成玉

绝经后骨质疏松症是女性常见疾病，严重影响生活质量。当前临床药物治疗虽有一定成效，但仍面临诸多挑战，如药物副作用、患者依从性差及个体差异等问题。通过个体化治疗方案、多学科协作、规范监测管理等策略优化，已取得一定进展，显著改善患者骨密度与生活质量，降低骨折风险。未来，随着新型药物研发、个性化治疗推进、多学科合作深化以及智能化管理应用，有望为患者提供更高效、精准的治疗方案，进一步提升绝经后骨质疏松症的防治水平。

绝经后骨质疏松症；临床药物治疗；现状；问题；优化策略

[1] 严艺云,姚增义,程萌.GREB1基因与绝经后骨质疏松症的研究进展[J].中国骨质疏松杂志,2025,31(04):592-596+603. [2] 纪涵,郭亚如,王姿璎,等.绝经后骨质疏松症风险预测模型系统评价[J].护理学报,2025,32(06):45-50. [3] 吴苗苗,施谧,毛娟娟,等.Caprini风险评估模式下质量控制路径对绝经后期骨质疏松症患者髋关节置换术后深静脉血栓发生率和关节功能的影响[J].中国妇幼保健,2025,40(05):821-825. [4] 朱衍,邱雷雨,卢焕兴.阿仑膦酸钠联合特立帕肽治疗绝经后骨质疏松症患者的临床研究[J].中国临床药理学杂志,2025, 41(01):26-30. [5] 杨艳,黄曙峰,潘海燕,等.绝经后骨质疏松症患者发生髋部骨折的危险因素分析[J].浙江创伤外科,2024,29(12):2332-2335. [6] 陈亚昆,刘武征,李文娟,等.绝经后骨质疏松症患者发生骨质疏松性骨折的危险因素分析[J].标记免疫分析与临床, 2024,31(12):2173-2181. [7] 甘卫冬,叶海程,樊孝俊,等.绝经后骨质疏松症患者PGI2､TXA2在骨代谢中的作用研究[J].中国卫生标准管理,2024,15(24):25-28. [8] 黄卫容.核心力量训练对绝经后骨质疏松症患者骨密度的影响[J].中外医药研究,2024,3(32):13-15. [9] 唐珍珍,陈霞,张雪梅.绝经后骨质疏松症患者椎体压缩性骨折发生现状､危险因素及干预对策分析[J].中外医疗,2024,43(31):44-47. [10] 马瑶.科学应对绝经后骨质疏松症,守护骨骼健康[J].健康生活,2024,(11):19-20. [11] Migliorini F,Maffulli N,Colarossi G,et al.Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis:a level I of evidence systematic review[J].European Journal of Medical Research,2025,30(1):170-170. [12] Zheng W H,Bui T A A,Ensrud E K,et al.Identifying Younger Postmenopausal Women With Osteoporosis Using USPSTF- Recommended Osteoporosis Risk Assessment Tools.[J].JAMA network open,2025,8(3):e250626. [13] Wu Y,Zhao C,Li Y,et al.Nomogram for predicting cemented vertebral refracture after percutaneous kyphoplasty in postmenopausal women with osteoporotic vertebral compression fractures[J].Clinical Neurology and Neurosurgery,2025,250108789-108789. [14] Xuan M,Wang B,Bi W,et al.Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field.[J].Aging clinical and experimental research,2025,37(1):44. [15] Mainar S A,Vilela S F,Soy S M,et al.Real-World Osteoporosis Treatment Gap and Costs in Spain:Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis.[J].Rheumatology and therapy,2025,12(2):1-21. [16] Ha J,Kim J,Jeong C,et al.Effects of denosumab and zoledronic acid on postmenopausal osteoporosis,bone density,and fat-free mass[J].Archives of Osteoporosis,2025,20(1):17-17. [17] F.S,A.S,H.C,et al.Effects of resistance training on microcirculation of bone tissue and bone turnover markers in postmenopausal women with osteopenia or osteoporosis:A systematic review[J].Clinical Hemorheology and Microcirculation,2025,89(1):161-174. [18] Cosman F,Wang Z,Li X,et al.Probability of Achieving Bone Mineral Density Treatment Goals with Denosumab Treatment in Postmenopausal Women with Osteoporosis.[J].Journal of bone and mineral research:the official journal of the American Society for Bone and Mineral Research,2025, [19] Chen T Z,Ge Y J,Jin S F,et al.The value of ultrasound measured rectus femoris thickness,cross-sectional area and shear wave velocity in assessment of muscle in postmenopausal women with osteosarcopenia.[J].The British journal of radiology,2025, [20] Yukishima T,Ebina K,Etani Y,et al.Impact of switching from bisphosphonates to denosumab,teriparatide,or romosozumab in patients with postmenopausal osteoporosis:a case–control study[J].Osteoporosis International,2025,36(3):1-8. [21] Ebina K,Kobayakawa T,Etani Y,et al.Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis:A case-control study.[J].Bone,2025,193117389. [22] Zheng Y,Sun R,Yang H,et al.Aucubin Promotes BMSCs Proliferation and Differentiation of Postmenopausal Osteoporosis Patients by Regulating Ferroptosis and BMP2 Signalling.[J].Journal of cellular and molecular medicine,2025,29(2):e70288. [23] Paul T,Garg B,Kapoor N,et al.A Prospective,Active-controlled,Randomized,Double-blind,Multicenter,Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis.[J].The Journal of the Association of Physicians of India,2025,73(1):ee8-e13. [24] Xue Y,Bao W,Huang W,et al.Relationship between neutrophil-to-lymphocyte ratio,monocyte-to-lymphocyte ratio,platelet-to- lymphocyte ratio and osteoporosis in postmenopausal type 2 diabetic patients:A retrospective study.[J].Medicine,2024,103(50):e40869. [25] Chung S Y,Langdahl B,Plebanski R,et al.SB16 versus reference denosumab in postmenopausal women with osteoporosis:18-month outcomes of a phase III randomized clinical trial.[J].Bone,2024,192117371.

点击下载PDF